The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Some people experience weight gain during treatment with Vraylar. While exercise may be helpful, it’s crucial not to overheat or dehydrate. Taking Vraylar can affect your metabolism, such as ...

Allergan's new launch Vraylar may have a chance in the crowded antipsychotic market, if it can shine at treating schizophrenia's “negative” symptoms, such as lack of emotion and loss of interest in ...

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication. The ...

Many people with major depressive disorder don’t get enough relief from their symptoms despite antidepressant medication. To potentially rectify the problem, the U.S. Food and Drug Administration (FDA ...

AbbVie’s antipsychotic Vraylar could get a major boost from a potential expansion into depression. But like some other late-stage contenders, the drug’s clinical results fell short of a home run.

DUBLIN and BUDAPEST, Hungary, Sept. 17, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc. announced today that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR™ ...

It’s not known whether Vraylar is safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether you should ...

The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy. The Food and Drug ...